跳至主要内容
临床试验/NCT01068964
NCT01068964已完成不适用

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Allergan0 个研究点目标入组 235 人开始时间: 2010年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
235
主要终点
The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4

研究概览

简要总结

This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily administered 0.5% Timolol Ophthalmic Solution concurrently in patients with open-angle glaucoma or ocular hypertension

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of open-angle glaucoma or ocular hypertension in one or both eyes
  • Eye pressure lowering topical medications are not working
  • Visual acuity is at least 0.2 in each eye

排除标准

  • Uncontrolled systemic disease
  • Any other active eye disease other than glaucoma or ocular hypertension
  • Significant visual field loss or evidence of progressive visual field loss within the last year
  • Anticipated wearing of contact lenses during the study
  • Required chronic use of other ocular medications during the study
  • Eye surgery or laser treatment within 12 weeks prior to study enrollment

研究组 & 干预措施

0.03% Bimatoprost/0.5% Timolol in Same Bottle

Experimental

Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution

干预措施: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution (Drug)

0.03% Bimatoprost and 0.5% Timolol in Separate Bottles

Active Comparator

Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution

干预措施: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution (Drug)

结局指标

主要结局

The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4

时间窗: Baseline, Week 4

The difference of change from baseline of mean diurnal IOP between the 0.03% Bimatoprost/0.5% Timolol in Same Bottle and the 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles at week 4. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of the study eye (the eye with the highest IOP at baseline) over the 3 time points measured at 8AM, 12PM and 4PM. A negative number change from baseline indicated a reduction (improvement) in IOP. The difference of change from baseline in IOP is presented in the statistical analysis section.

次要结局

未报告次要终点

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验